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Abstract
In this case study, different measures aimed at preventing cardiovascular diseases (CVD) in different
target groups have been ranked based on cost per QALY from a health care sector perspective
and from a societal perspective, respectively. The innovation in this study is to introduce a budget
constraint and thereby show exactly which groups would be included or excluded in treatment or
intervention programs based on the two perspectives. Approximately 90% of the groups are
included in both perspectives. Mainly elderly women are excluded when the societal perspective is
used and mainly middle-aged men are excluded when the health care sector perspective is used.
Elderly women have a higher risk of CVD and generally lower income than middle-aged men. Thus
the exclusion of older women in the societal perspective is not a trivial consequence since it is in
conflict with the general interpretation of the "treatment according to need" rule, as well as societal
goals regarding gender equality and fairness. On the other hand, the exclusion of working
individuals in the health care perspective undermines a growth of public resources for future health
care for the elderly. The extent and consequences of this conflict are unclear and empirical studies
of this problem are rare.
Introduction
Cost-effectiveness analysis is often considered to be a sim-
ple and straightforward tool for resource allocation deci-
sions. However, there are many unsolved methodological
controversies debated in the literature, such as the choice
of perspective. Many economists recommend a societal
perspective based on welfare economics rooted in utilitar-
ian philosophy. The goal of society is commonly assumed
to be the maximization of utility, irrespective of distribu-
tion. A state with a higher sum of utility is always preferred
to a state with a lower sum. However, such a framework
raises equity concerns and the use of social welfare func-
tions are a possible solution but are still rare in empirical
studies.
Adopting the maximization view in the evaluation of
health care programs means that all health effects, costs
and savings should be considered independently of the
identity of the beneficiary and payer. One important but
controversial aspect of this is productivity changes as a
consequence of health care interventions [1]. From a soci-
etal perspective, these productivity changes should always
be included in cost-effectiveness analyses, usually in the
numerator. However, there are many opponents to this
view and their main argument is fairness – it is not fair to
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include productivity changes as a savings factor in the cal-
culus because it will discriminate against people with low
income (women, pensioners, ethnic minorities, immi-
grants etc.). A response to this critique has been the use of
a "standard" income figure, equal for all individuals in
full-time employment [1].
In addition to fairness, some argue that the application of
the societal perspective in health implies an imbalance
because the effect side is only focused on health and there-
fore it may be considered inconsistent to include all costs.
Brower et al [2] describe a responsibility argument. Deci-
sion-makers in health care commonly interpret their man-
date as maximizing health gains subject to the resources
devoted for this purpose. Thus it is natural for them to
only be concerned with the costs and savings that affect
the specific budget they are responsible for. This in turn
causes the analysts to choose a health care sector perspec-
tive. Yet, Brouwer et al [2] suggest the adoption of a two-
perspective approach as standard.
In addition to the way in which productivity changes are
dealt with, there are several important differences between
the societal perspective and the health sector perspective,
such as their differing treatment of costs incurred by the
patient and/or the family and voluntary caring time. In
the current study, however, we focus on the issue of pro-
ductivity changes.
The precise consequences of including or excluding pro-
ductivity changes depends of course on the specific con-
text, but in general the consequences are that some
patients are treated while others are denied treatment
(assuming that decision-makers base their decisions on
the findings of cost-effectiveness analyses). It is unlikely
that exactly the same groups will be denied treatment
based on the two perspectives. Despite general awareness
of the consequences of the different perspectives, how-
ever, quantifications are rare. We have not found any stud-
ies attempting to show who will receive and who will be
denied treatment in either a societal or health care sector
perspective.
In order to make the consequences of the differing per-
spectives explicit, the whole process of cost-effectiveness
analysis must be outlined. This process has been
described as:
"Most often, CEA is applied from a societal viewpoint or
from the viewpoint of a national health care system. In
this formulation, the implied decision-maker is an agent
for society at large, and the objective is to achieve the max-
imum possible health benefit (e.g. life years, or quality-
adjusted life years [QALY's]) subject to overall limits on
health-care resources. [3]
However, to our knowledge there have been few attempts
in the literature to carry out the whole process of CEA (we
are aware of only two: [4,5]).
The aims of this case study are:
A. To show exactly which groups will be excluded from
treatment based on a health care sector perspective and a
societal perspective respectively;
B. Decompose the ratios and examine the opportunity
costs (and QALY's) of a health sector perspective.
Methods
The case used in this study is the prevention of CVD. An
intervention is defined as an effort with the purpose of
reducing CVD risk in a defined target group and each
intervention thus has the capacity to prevent CVD and
produce QALYs. At the same time, interventions also con-
sume resources from the available budget. This amount of
resources can be considered as a monetary measure of
"need". Culyer and Wagstaff [6] suggest a definition of
need relevant to economics: "the minimum amount of
resources required to exhaust a person's capacity to bene-
fit i.e. the costs necessary to satisfy a need during a certain
time period (e.g. one year)".
The cost of applying an intervention in a target group is
equal to the number of people in the target group multi-
plied by the cost per person.
Savings are based on prevented cases of CVD and they are
calculated according to the two perspectives – a societal
and a health care sector perspective.
The budget is defined as the actual direct cost of the inter-
ventions, i.e. the proportion of the set (the "needs") that
are financed today.
We use a deterministic model to compute the effect of an
intervention. The starting point is a cohort of CVD-free
individuals. Every year the cohort is exposed to the risk of
suffering a myocardial infarction (MI), suffering a stroke,
or death from other causes.
Separate risk functions were used for MI and stroke. The
one-year risk of a MI or a stroke is the annual age- and sex-
specific incidence adjusted for the difference between the
risk factor level in a studied group and the mean risk factor
level in the population [7]. To estimate non-fatal and fatal
incidences, the Swedish Hospital Patient Discharge Regis-
ter and the Cause of Death Register were used respectively
[8].Cost Effectiveness and Resource Allocation 2008, 6:6 http://www.resource-allocation.com/content/6/1/6
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The costs included for the interventions are drugs and
smoking cessation (table 1), and hospital treatment and
production loss relating to manifest disease (table 2). In
the societal perspective (table 1), the patient's travel costs
as well as their co-payment for drug costs are added. The
value of production was estimated as the difference
between the annual gross income for the patients with an
MI or stroke and the general population. The estimations
were based on all patients between 1995 and 1998 in Swe-
den using the Swedish Hospital Patient Discharge Regis-
ter, the Cause of Death Register and data of income
registered at Statistics Sweden [8,9]. The hospital treat-
ment costs are a result of MI or stroke and are stratified
according to the first year and all subsequent following
years. The QALY weights are obtained from the literature
[10].
Three interventions to prevent CVD are included in this
study: smoking cessation advice; hypertension drugs; and
cholesterol drugs. A single intervention or a combination
of two or three may be taken. Thus there are a total of eight
different possible intervention strategies and it is neces-
sary to analyse the incremental effects and costs of each.
The health gains of any particular intervention depend,
among other things, on the risk of the target group. There-
fore, the population is stratified according to risk into 108
groups (table 3).
The effect of cholesterol-lowering drugs is assumed to be
a 20% reduction in the yearly risk for both MI and stroke
[11,12]. The effect of blood pressure lowering drugs is
assumed to be a 16% reduction in risk for MI and 38%
risk reduction for stroke [13]. The effect of smoking cessa-
tion is a 45% reduction in the yearly risk of MI and a 49%
reduction in the yearly risk of stroke [14].
We calculated the cost per QALY in two ways, according to
two sets of cost components in table 1 and 2, and produc-
tivity gains were only included in calculations based on
the societal perspective. Budget claims was set as equal to
"local needs", which were calculated as the number of per-
sons belonging to certain risk groups (and thus the popu-
lation that could expect improved health from the
intervention) multiplied by the direct intervention cost
per person. The county council budget for a certain pur-
pose is equal to the amount of resources currently used for
that specific purpose. In total, the resources spent on pri-
mary prevention of CVD with drugs and smoking cessa-
tion in Västerbotten county council is 36.5 million SEK
and this amount is used as a budget constraint in the cal-
culations. All the interventions were ranked, initially
according to the cost-effectiveness ratio based on societal
costs, and subsequently on the ratio including health care
costs only. Thus two different rankings of each interven-
tion up to the budget limit are presented here.
Table 1: Costs of different interventions (SEK) in two perspectives.
Intervention Cost (SEK)
Health care sector perspective Societal perspective
Smoking cessation 150 150
Blood pressure reduction 2284 3122
Cholesterol reduction 3641 4600
Blood pressure reduction and smoking cessation 2434 3272
Cholesterol reduction and smoking cessation 3791 4750
Blood pressure reduction and cholesterol reduction 4725 6182
Blood pressure reduction, cholesterol reduction and smoking cessation 4875 6332
Table 2: Assumed costs (tSEK) for production losses and hospital treatment, and QALY-weights.
1st year Subsequent years
Female Male Female Male
40–49 50–64 40–49 50–64 40–49 50–64 40–49 50–64
MI S MI S MI S MI S MI S MI S MI S MI S
Production losses 60 55 66 66 67 71 68 83 55 70 83 85 70 94 85 113
Hospital treatment 59 72 59 72 59 72 59 72 8 54 8 54 8 54 8 54
QALY-weight 0.75 0.5 0.75 0.5 0.75 0.5 0.75 0.5 0.95 0.75 0.95 0.75 0.95 0.75 0.95 0.75Cost Effectiveness and Resource Allocation 2008, 6:6 http://www.resource-allocation.com/content/6/1/6
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Results
Altogether 160 combinations of groups and treatments
were not dominated and constitute the complete "league-
table" in this study. 94 groups would be given the same
treatment in both perspectives even if the ranking order
differed. Twelve groups (notations A to L) are included
either in the societal or the health care sector perspective
(table 4). 57 groups were excluded from treatment using
the societal perspective and 63 groups using the health
care sector perspective. The group A-I contains 4053 indi-
viduals and the group J-L 4039, so the treatment costs are
equal (figures not shown). In the societal perspective, A to
I have ratios equal to or below 54101 SEK/QALY and are
included while J to L have ratios equal to or larger than
54855 SEK/QALY. In the health care sector perspective, J
to K have the lowest ratios (59413–77047 SEK/QALY)
and are included, while A-I have ratios of 79599 SEK/
QUALY or greater, and are thus excluded. The main pat-
tern is that older females (J-L) are included in the health
care sector perspective only, while primarily younger
males and some females (A-I) are included in the societal
perspective only.
The two perspectives will cause different consequences on
the margin measured as gained QALY's and net costs.
Comparing A-I with J-L, the former interventions have a
93 million lower net cost (71289 tSEK versus 164760
tSEK), while the latter (J-L) gains 729 more QALY's. From
a health maximization point of view, the health care sec-
tor perspective must be preferable. From a welfare maxi-
mization point of view, the situation is unclear.
Discussion
This is a case study bearing the inherent limitations
regarding generalization. However, only empirical studies
can provide the information necessary for a deeper under-
standing of the potential conflict between the two CEA
perspectives. Not even the most convinced advocates for a
certain principle are likely to be completely insensitive to
the size of the sacrifices one has to make when principles
clash.
Our calculations show that the ranking order is sensitive
to the choice of perspective but, in general, when a budget
constraint is introduced the same groups will receive treat-
ment. Therefore one can say that the choice of perspective
is only important for those groups close to the budget
line.
The health care sector perspective is more effective in pro-
ducing health gains. If the calculations are further decom-
posed, age is a critical factor in several respects:
1. The risk for disease increases with age.
Table 3: Combination of risk factors used in the stratification of 
the population.
Age 40 – 49, 50 – 59, 60 – 69
Sex Female, Male
Smoking Yes, No
Cholesterol -5,9 mmol/l, 6,0–7,4 mmol/l, 7,5 mmol/l -
Blood pressure -139 mmHg, 140–179 mmHg, 180 mmHg -
Table 4: Treatment groups either excluded in the societal or health care sector perspective
Intervention Sex and age Risk profile Gained QALYs Societal perspective Health care sector perspective
Net costs, SEK Cost/QALY Included Net costs, SEK Cost/QALY Included
AM 40 5.0, 180 6 1 167 Yes 606 101000 No
BM 40 S, 6.0, 150 90 434 4822 Yes 7947 88300 No
CM 40 S, 7.5, 139 63 1045 16587 Yes 6451 102397 No
DM 50 S, 5.0, 150 147 3036 20653 Yes 12194 82952 No
EM 40 7.5, 150 68 1772 26059 Yes 7105 104485 No
FM 50 S, 6.0, 139 346 13254 38306 Yes 32258 93231 No
GM 50 6.0, 150 624 26209 42002 Yes 58805 94239 No
HF 50 S,6.0,150 247 13257 53672 Yes 19661 79599 No
IM 50 7.5, 139 227 12281 54101 Yes 23964 105568 No
A-I 1812 71289
JF 60 7.5, 150 765 41964 54855 No 45451 59413 Yes
KF 60 6.0,150 1541 105851 68690 No 112247 72841 Yes
LF 60 S,6.0,139 235 16945 72106 No 18106 77047 Yes
J-L 2541 164760
M = male
F = female
SEK = Swedish Crowns
5.0, 6.0, 7.5 = cholesterol levels
139, 150, 180 = blood pressure levelsCost Effectiveness and Resource Allocation 2008, 6:6 http://www.resource-allocation.com/content/6/1/6
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2. The accumulated gains counted as QALYs are larger the
younger the person is at the time of the prevented event
(ceteris paribus).
3. The cost for a continuous treatment such as hyperten-
sion drugs are larger the younger the person is at the time
of the initiation of treatment. "Point interventions" such
as smoking advice have the same costs independent of
age.
4. The accumulated production losses are larger the
younger the person is at the time of the prevented event.
The production losses normally approach zero soon after
retirement.
Points 1–3 above are common for the two perspectives. In
the health sector perspective the higher risk and lower
treatment costs for old women outweigh the longer dura-
tion of the gaining period for younger males. However, in
the societal perspective the latter have a higher lifetime
income resulting in larger productivity gains in the case of
successful prevention and thus a lower net cost. This pat-
tern would be even more pronounced if individuals aged
over 60 were included in the study. Initially, our intention
was to include individuals up to 70 years of age since they
have almost completely left the labour-market, however
this proved to be impossible because epidemiological
data for that age-group were not available.
In the example used here (CVD) the risk of disease
increases sharply with age thereby compensating for
declining income in the ratio calcuation. This example is
likely to be representative of many diseases since inci-
dence is often positively correlated with age.
Productivity changes is not the only components in the
calculations that are controversial from a normative point
of view. It has been argued that QALY's are ageist because
younger people typically have a longer life expectancy and
treatment of younger individuals thus yields more QALYs
than similar treatment of older people [15]. The counter
argument is best known as the "fair innings" argument
[16], which argues that everyone is entitled to a fair
innings of life, and the old have had more of their innings
than the young. This position receives some support from
several empirical studies indicating that people in general
want to give priority to the young over the old [17,18].
However, there exist two qualitatively different reasons for
this standpoint. One has its roots in equity considerations
– the young have lived less than the old. The second is
based on efficiency considerations – the benefit to society
is larger if priority is given to young people.
One circumstance making this even more complicated is
the dependence between the health of the working popu-
lation and public resources for health and elderly care.
Olsen and Richardson [19] investigate this dilemma and
argue that most publicly funded health care is based on
the principle of "equal access for equal need", meaning
that a health gain has the same social value irrespective of
the income level of the beneficiaries. Thus it would be
wrong to exclude older women. But a dilemma arises if
economic evaluations strive to incorporate this principle.
On one hand, the fact that a patient's priority depends on
his income is in conflict with "equal access for equal
need". On the other hand, to disregard increased produc-
tivity gains means ignoring increased societal welfare,
which is the fundamental core of welfare economics.
Brouwer et al.[2] discuss the conflict between the broad
societal perspective and the more narrow perspective of
health care decision-makers. In some European countries,
decision-makers have a democracy mandate, they are
responsible for a certain budget and equity goals are
important. This creates tension between the two perspec-
tives and, assuming that the purpose of health economic
analyses is to aid decision-makers, one can question if all
dollars have the same value. "We conclude that although
all costs are equal, in a health economic evaluation, some
may be more equal than others." [2 p 347]
To summarize, allocating health care resources often
requires a trade off between conflicting principles. An
ambition to establish a general balance seems to imply
futile efforts. Rather, the balance has to be set from case to
case. Baltuseen and Niessen [20] have proposed a multi-
criteria analysis for priority setting in health care, and we
believe this would be a step towards more appropriate
assistance to the decision-makers. It has been argued that
an analysis in two perspectives would be a part of such a
development, and we agree. However, we want to add that
more studies making the consequences of different per-
spectives visible would be a further step forward. Who will
be treated and who will not? Thus we need to involve the
cost-effectiveness studies in a budgetary context more
often.
Conclusion
In this case study, roughly the same groups are prioritised
for treatment in the two perspectives. The exclusion of old
women in the societal perspective is, however, not a trivial
consequence from equity or fairness points of view. On
the other hand, the exclusion of young working males in
the health care perspective decreases, in principle, societal
resources available for future health and elderly care.
Whether, this is a typical or an infrequent case is not clear
because empirical studies of this problem are lacking. We
thus demand more "case studies" in order to increase our
understanding of the potential conflict between the two
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